Skip to main content

BREAKING: CMS Releases Step Therapy Rule; Academy Comments Net Impact on New-Starts Requirement  

Our early review of the rule concludes that CMS has agreed to an Academy request that it adjust its definition of new starts of treatment.

The Centers for Medicare & Medicaid Services today released its final rule governing step therapy in Medicare. The policy applies to current Medicare Advantage and Part D plan utilization tools – for example, prior authorization and step therapy – for Part B drugs. As such, it affects those used by ophthalmologists for treating age-related macular degeneration and other retinal conditions. The rule outlines requirements, including specific patient protections for plans starting in 2020.

The Academy is working with a law firm to review the final rule and will keep the membership advised as we analyze this new policy in-depth.

Our early review of the rule concludes that CMS has agreed to an Academy request that it adjust its definition of new starts of treatment. When the proposed rule was released, CMS limited step therapy to new starts, which included a 108-day lookback period for determining when treatment with a certain drug therapy began. Now, CMS is setting that lookback period at one year.

Related Stories

Member exclusive - Locked
Step therapy has to go

Federal Watchdog to Investigate Step Therapy in Medicare Advantage Plans, at Academy’s Urging

The Academy met with the HHS Office of Inspector to continue pressing our concerns about step therapy. The meeting follows the OIG’s September 15 announcement that it will review how Medicare Advantage plans use prior authorization and step therapy for Part B drugs, a review the Academy urged.  
 

Member exclusive - Locked Fallback image

Advocacy Works: Academy Pushes Humana to Correct 1.8 Million Denied Claims

Responding to members, the Academy fought Humana's mass denials and won. Here's what your practice needs to know to recover affected payments.

Member exclusive - Locked Fallback image

Advocacy Works: Humana Backs Down on Claim Denials

When Humana started denying valid claims for office and eye visits billed with diagnostic testing, the Academy fought back — and won.

Latest Updates

Member exclusive - Locked
capital building side

OPHTHPAC Midterms Recap: What the Results Mean for Ophthalmology

The 2026 midterm results are nearly final, and thanks to the support of ophthalmologists nationwide, OPHTHPAC helped secure important victories for ophthalmology this election cycle: 100 of 114 OPHTHPAC-backed candidates won their general election races, with a few results still being finalized. Here is what this year’s results mean for ophthalmology.

Member exclusive - Locked
capital building side

Final Hospital Outpatient, ASC Rule: Pay Raises for Device-Intensive Procedures, But Cuts to Other Common Ophthalmic Surgeries

Hospital outpatient departments (HOPD) and ambulatory surgical centers will get a 2.3% payment increase in 2027. But the rule released Nov. 4 by the Centers for Medicare & Medicaid Services includes hidden reimbursement cuts for most ophthalmology surgeries.

Member exclusive - Locked
HHS

2027 Fee Schedule Finalizes Pay Cut to Physicians Between 1.8% and 2.3%

The final rule from the Centers for Medicare & Medicaid Services (CMS) includes a 2.31% payment cut for physicians not participating in qualifying APMs and a 1.83% pay cut for qualifying Alternative Payment Model (APM) participants.